TY - JOUR
T1 - Classification, risk factors, and management of lumen apposing metal stent dysfunction during follow-up of endoscopic ultrasound-guided choledochoduodenostomy
T2 - Multicenter evaluation from the Leuven-Amsterdam-Milan Study Group
AU - Vanella, Giuseppe
AU - Bronswijk, Michiel
AU - Dell'Anna, Giuseppe
AU - Voermans, Rogier P.
AU - Laleman, Wim
AU - Petrone, Maria Chiara
AU - van Malenstein, Hannah
AU - Fockens, Paul
AU - Arcidiacono, Paolo Giorgio
AU - van der Merwe, Schalk
AU - van Wanrooij, Roy L. J.
N1 - Funding Information:
Author M.B. has consultancy agreements with Taewoong and Prion Medical, receives travel grants from Taewoong, Norgine, and Prion Medical, and receives medical device support from Taewoong and Prion Medical. W.L. co‐chairs the Boston Chair in Interventional Endoscopy and has consultancy agreements with Boston Scientific and Cook Medical. H.v.M. has consultancy agreement with Boston Scientific. P.F. has consultancy agreements with Olympus and Cook Medical. S.v.d.M. co‐chairs the Boston Chair in Interventional Endoscopy, holds the Cook Chair in the study of portal hypertension, has consultancy agreements with Boston Scientific, Cook Medical, and Pentax, and reports participation in the Board of Boston Scientific and Cook Medical. R.P.V. has consultancy agreement with Boston Scientific and receives research grants from Boston Scientific. R.L.J.v.W. has consultancy agreement with Boston Scientific. G.V. and G.D. report travel grants from Pentax Medical. The other authors declare no conflict of interest for this article.
Publisher Copyright:
© 2022 The Authors. Digestive Endoscopy published by John Wiley & Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.
PY - 2022
Y1 - 2022
N2 - Objectives: Long-term outcomes of endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) performed with lumen apposing metal stents (LAMS) have been poorly evaluated in small or retrospective series, leading to an underestimation of LAMS dysfunction. Methods: All consecutive EUS-CDS performed in three academic referral centers were included in prospectively maintained databases. Technical/clinical success, adverse events (AEs), and dysfunction during follow-up were retrospectively analyzed. Kaplan–Meier analysis was used to estimate dysfunction-free survival (DFS), with Cox proportional hazard regression to evaluate independent predictors of dysfunction. Results: Ninety-three patients were included (male 56%; mean age, 70 years [95% confidence interval (CI) 68–72]; pancreatic cancer 81%, metastatic disease 47%). In 67% of procedures, 6 mm LAMS were used. Technical and clinical success were achieved in 97.8% and 93.4% of patients, respectively, with AEs occurring in 9.7% (78% mild/moderate). Dysfunction occurred in 31.8% of patients after a mean of 166 days (95% CI 91–241), with an estimated 6 month and 12 month DFS of 75% and 52%, respectively; mean DFS of 394 (95% CI 307–482) days. Almost all dysfunctions (96%) were successfully managed by endoscopic reintervention. Duodenal invasion (hazard ratio 2.7 [95% CI 1.1–6.8]) was the only independent predictor of dysfunction. Conclusions: Endoscopic ultrasound-guided choledochoduodenostomy shows excellent initial efficacy and safety, although stent dysfunctions occurs frequently during long-term follow-up. Almost all stent dysfunctions can be managed successfully by endoscopic reinterventions. We propose a comprehensive classification of the different types of dysfunction that may be encountered and rescue procedures that may be employed under these circumstances. Duodenal invasion seems to increase the risk of developing EUS-CDS dysfunction, potentially representing a relative contraindication for this technique.
AB - Objectives: Long-term outcomes of endoscopic ultrasound-guided choledochoduodenostomy (EUS-CDS) performed with lumen apposing metal stents (LAMS) have been poorly evaluated in small or retrospective series, leading to an underestimation of LAMS dysfunction. Methods: All consecutive EUS-CDS performed in three academic referral centers were included in prospectively maintained databases. Technical/clinical success, adverse events (AEs), and dysfunction during follow-up were retrospectively analyzed. Kaplan–Meier analysis was used to estimate dysfunction-free survival (DFS), with Cox proportional hazard regression to evaluate independent predictors of dysfunction. Results: Ninety-three patients were included (male 56%; mean age, 70 years [95% confidence interval (CI) 68–72]; pancreatic cancer 81%, metastatic disease 47%). In 67% of procedures, 6 mm LAMS were used. Technical and clinical success were achieved in 97.8% and 93.4% of patients, respectively, with AEs occurring in 9.7% (78% mild/moderate). Dysfunction occurred in 31.8% of patients after a mean of 166 days (95% CI 91–241), with an estimated 6 month and 12 month DFS of 75% and 52%, respectively; mean DFS of 394 (95% CI 307–482) days. Almost all dysfunctions (96%) were successfully managed by endoscopic reintervention. Duodenal invasion (hazard ratio 2.7 [95% CI 1.1–6.8]) was the only independent predictor of dysfunction. Conclusions: Endoscopic ultrasound-guided choledochoduodenostomy shows excellent initial efficacy and safety, although stent dysfunctions occurs frequently during long-term follow-up. Almost all stent dysfunctions can be managed successfully by endoscopic reinterventions. We propose a comprehensive classification of the different types of dysfunction that may be encountered and rescue procedures that may be employed under these circumstances. Duodenal invasion seems to increase the risk of developing EUS-CDS dysfunction, potentially representing a relative contraindication for this technique.
KW - biliary drainage
KW - choledochostomy
KW - pancreatic neoplasm
KW - stent
KW - therapeutic endoscopic ultrasound
UR - https://www.scopus.com/pages/publications/85141730237
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85141730237&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36177532
U2 - 10.1111/den.14445
DO - 10.1111/den.14445
M3 - Article
C2 - 36177532
SN - 0915-5635
JO - Digestive endoscopy
JF - Digestive endoscopy
ER -